http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2146742-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_48b71c68297a164780b7b2469943ad79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9dc4fe8e31389273b83323e26548c443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84bf3df3c637864eb72d38d2bb2eee7a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-876 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00119 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 |
| filingDate | 2008-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbecbe5b1dbf64d6213a7e32e5a1b465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86c7949996a7e3517017d6f68a7f6cc8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7ca88fc7987a4939765b86af1206d7e |
| publicationDate | 2012-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2146742-B1 |
| titleOfInvention | Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods |
| abstract | CeIl lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods. More particularly, the invention relates to diverse human melanoma cell lines for the treatment of malignant diseases, wherein the cell lines are: (a) MeI-XYl (deposited at German Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2830), (b) Mel-XY2 (deposited at Germán Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2831), (c) Mel-XY3 (deposited at Germán Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2832), (d) Mel-XX4 (deposited at Germán Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2829), or (e) sub-populations thereof. The cell lines may be irradiated, thus obtaining populations with apoptotic phenotype, and populations with necrotic phenotype of such lines. The compositions may comprise adjuvants and/or immuno-modif iers, and/or autologous dendritic cells. |
| priorityDate | 2007-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.